Free Trial
NASDAQ:ITOS

iTeos Therapeutics Q2 2024 Earnings Report

iTeos Therapeutics logo
$7.77 +0.27 (+3.60%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$7.77 0.00 (0.00%)
As of 05/2/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iTeos Therapeutics EPS Results

Actual EPS
-$0.18
Consensus EPS
-$1.04
Beat/Miss
Beat by +$0.86
One Year Ago EPS
N/A

iTeos Therapeutics Revenue Results

Actual Revenue
$35.00 million
Expected Revenue
$4.20 million
Beat/Miss
Beat by +$30.80 million
YoY Revenue Growth
N/A

iTeos Therapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

iTeos Therapeutics' Q2 2025 earnings is scheduled for Friday, May 9, 2025

iTeos Therapeutics Earnings Headlines

Q2 EPS Estimates for iTeos Therapeutics Reduced by Wedbush
Q2 EPS Forecast for iTeos Therapeutics Lifted by Analyst
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More iTeos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iTeos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iTeos Therapeutics and other key companies, straight to your email.

About iTeos Therapeutics

iTeos Therapeutics (NASDAQ:ITOS) is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

View iTeos Therapeutics Profile

More Earnings Resources from MarketBeat